Doxepin: Clinical Overview
Doxepin is a tricyclic antidepressant indicated primarily for depression, anxiety, and insomnia, with low doses (3-6 mg) specifically FDA-approved for sleep maintenance insomnia and higher doses (75-300 mg) for depression and anxiety disorders. 1
Primary Indications
FDA-Approved Uses 1
Depression and Anxiety (Higher Doses):
- Psychoneurotic patients with depression and/or anxiety
- Depression/anxiety associated with alcoholism (not to be taken with alcohol)
- Depression/anxiety associated with organic disease
- Psychotic depressive disorders with associated anxiety, including involutional depression and manic-depressive disorders
Insomnia (Low Doses):
- Sleep maintenance insomnia is the primary indication for low-dose doxepin (3 mg and 6 mg), with clinically significant improvements in wake after sleep onset (WASO), total sleep time (TST), and sleep efficiency. 2
Off-Label Uses
Pruritus Management:
- Topical doxepin (5% cream) for generalized pruritus, limited to 8 days of use, maximum 10% body surface area, and 12 g daily due to contact dermatitis risk 3
- Oral low-dose doxepin (10 mg three times daily) for pruritus associated with allergic cutaneous reactions when conventional antihistamines fail 4
Dosing Recommendations
For Depression/Anxiety 1
Initial Dosing:
- Mild to moderate severity: Start 75 mg daily
- Adjust at appropriate intervals based on response
- Usual optimum range: 75-150 mg/day
Severe Illness:
- May require higher doses with gradual increase to 300 mg/day maximum
- Additional therapeutic effect rarely obtained beyond 300 mg/day
Mild Symptomatology:
- May suffice with 25-50 mg/day
Administration:
- Can be given as divided doses or once-daily (maximum 150 mg for once-daily dosing)
- Once-daily dosing should be given at bedtime
- The 150 mg capsule is for maintenance only, not treatment initiation
For Insomnia 2
Evidence-Based Dosing:
- 3 mg or 6 mg nightly
- Both doses show clinically significant improvements in WASO (22-23 min reduction vs placebo) and TST (26-32 min increase vs placebo)
- 6 mg shows mild increase in somnolence compared to 3 mg
- Minimal effect on sleep latency at either dose
For Pruritus 3, 4
Topical:
- Apply to affected areas
- Maximum 8 days duration
- Maximum 10% body surface area
- Maximum 12 g daily
Oral:
- 10 mg three times daily for allergic cutaneous reactions
Special Population Considerations
Elderly Patients 1
- Start on low doses and observe closely
- More likely to have decreased renal function requiring dose adjustment
- Sedating effects may cause confusion and oversedation
- Elderly patients were successfully studied at 3-6 mg for insomnia 2
Pediatric Patients 1
- Not recommended for children under 12 years due to lack of clinical experience
- Case report of chronic toxicity in a 10-year-old at 4.41 mg/kg (300 mg) highlights significant risk 5
Pharmacogenomic Considerations 6, 7, 5
- CYP2D6 and CYP2C19 polymorphisms cause significant interindividual variability
- Blood level monitoring can optimize dosing in subtherapeutic responders
- Age affects clearance (CL/F decreases with age)
- Body weight affects volume of distribution
- Therapeutic plasma level: 100-300 ng/mL combined doxepin-nordoxepin
Contraindications 1
Absolute Contraindications:
- Hypersensitivity to doxepin or other dibenzoxepines
- Glaucoma
- Urinary retention tendency
Important Warnings:
- Black Box Warning: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) with major depressive disorder 1
- Risk differences by age: <18 years (14 additional cases per 1000), 18-24 years (5 additional cases per 1000)
- Adults ≥65 years show 6 fewer cases per 1000 compared to placebo
Drug Interactions and Precautions
Critical Interactions 1, 7, 5
- CYP2D6 inhibitors (e.g., clobazam) and CYP2C19 inhibitors (e.g., topiramate) can precipitate toxicity
- Co-medication inhibiting P450 isoenzymes lowers clearance by 15%
- At doses >150 mg/day, may block antihypertensive effects of guanethidine and related compounds
- Alcohol contraindicated when treating alcohol-associated depression
Monitoring Requirements 6
- Blood level monitoring recommended for patients unresponsive to typical doses
- Therapeutic range: 100-300 ng/mL (combined doxepin-nordoxepin)
- Consider pharmacogenomic testing (CYP2D6, CYP2C19) for optimization
Adverse Effects
Common Side Effects 2, 1
Low-Dose (3-6 mg for insomnia):
- Headache
- Somnolence (mild increase at 6 mg)
- Diarrhea
- Upper respiratory infection
Higher Doses (Depression/Anxiety):
- Drowsiness (most common, tends to disappear with continued therapy)
- Anticholinergic effects: dry mouth, blurred vision, constipation, urinary retention
- Cardiovascular: hypotension, hypertension, tachycardia
- CNS: confusion, disorientation, hallucinations, ataxia, seizures
- Hematologic: eosinophilia, rare bone marrow depression
Serious Adverse Events 1, 8, 5
- Drug abuse potential identified in pharmacovigilance data 8
- Chronic toxicity can mimic epilepsy with confusion, ataxia, and seizures 5
- QRS prolongation on ECG indicates toxicity
- Withdrawal symptoms possible with abrupt cessation after prolonged use
Alternative Therapies
For Sleep Maintenance Insomnia 2
Other Recommended Agents:
- Eszopiclone (2-3 mg): TST improvement 28-57 min, WASO reduction 10-14 min, moderate-to-large sleep quality improvement
- Suvorexant (10-20 mg): TST improvement 10 min, WASO reduction 16-28 min
- Zolpidem (10 mg): TST improvement 29 min, WASO reduction 25 min, moderate sleep quality improvement
- Temazepam (15 mg): TST improvement 99 min, small sleep quality improvement
For Depression/Anxiety 1
- Other tricyclic antidepressants
- SSRIs and SNRIs (preferred first-line in younger patients due to suicide risk profile)
- Cognitive behavioral therapy for insomnia (CBT-I) as non-pharmacological option
Clinical Pearls and Pitfalls
Key Advantages:
- Most potent H1 antihistamine receptor antagonist at low doses 9
- Dual H1 and H2 blocking properties for pruritus 4
- No physical tolerance or psychological dependence 1
- Anti-anxiety effect appears before antidepressant effect (optimal antidepressant effect may take 2-3 weeks) 1
Common Pitfalls to Avoid:
- Do not label treatment failures without considering blood level monitoring—inadequate dosing due to pharmacogenomic variability is common 6
- Do not exceed 8 days for topical use due to contact dermatitis risk 3
- Do not abruptly discontinue after prolonged use—taper gradually to avoid withdrawal symptoms 1
- Do not overlook drug interactions with CYP2D6/2C19 inhibitors that can cause toxicity 5
- Monitor for QRS prolongation on ECG as indicator of toxicity 1